Market revenue in 2023 | USD 941.6 million |
Market revenue in 2030 | USD 1,453.9 million |
Growth rate | 6.4% (CAGR from 2023 to 2030) |
Largest segment | Synthetic |
Fastest growing segment | Biotech |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Synthetic, Biotech |
Key market players worldwide | Basf SE, CordenPharma, Bristol-Myers Squibb Co, Pfizer Inc, Boehringer Ingelheim Pharma, Dr. Reddy’s Laboratories, Sun Pharmaceutical Industries, Albany Molecular Research, Sanofi SA, Lonza Group Ltd, Cipla Ltd DR, Merck & Co Inc, Teva Pharmaceutical Industries Ltd, Novartis AG ADR, Roche Holding AG |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to high potency active pharmaceutical ingredients market will help companies and investors design strategic landscapes.
Synthetic was the largest segment with a revenue share of 72.12% in 2023. Horizon Databook has segmented the UK high potency active pharmaceutical ingredients market based on synthetic, biotech covering the revenue growth of each sub-segment from 2018 to 2030.
Rising R&D coupled with high incidence of chronic diseases are among the major factors driving the UK high potency active pharmaceutical ingredients market. According to Cancer Research UK, over 367,000 new cancer cases were diagnosed in 2017. Statistics from the same source indicate that over 165,000 deaths occurred as a result of cancer in 2017.
The number increased to 446,942 new cases in 2018. Prostate, breast, lung, bowel, kidney, oral, esophageal cancers, malignant melanoma, Non-Hodgkin Lymphoma, and leukemia are some of the most common types of cancer in the UK. According to the UK Bioindustry Association (BIA), the UK life sciences ecosystem raised over GBP 1.3 billion investment in 2019.
Furthermore, in 2019, Cancer Research UK announced biotech investment fund of GBP 200 million. This allows companies to focus on the development of oncology treatment. These factors indicate rising R&D in the nation, which is boosting the demand for biopharmaceutical and pharmaceutical products.
Horizon Databook provides a detailed overview of country-level data and insights on the UK high potency active pharmaceutical ingredients market , including forecasts for subscribers. This country databook contains high-level insights into UK high potency active pharmaceutical ingredients market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account